title: Locally advanced differentiated thyroid carcinoma: a 35-year mono-institutional experience in 280 patients.
abstract: OBJECTIVE
  Debate exists in the literature about the optimal treatment to be adopted in patients with locally advanced differentiated thyroid carcinoma. We aimed to better define the most appropriate diagnostic and therapeutic protocol for this type of tumour.
  
  
  METHODS
  The clinical and histopathological records of 280 consecutive patients with locally advanced differentiated thyroid carcinoma, studied and operated on by the same surgical team in the period between 1967 and 2002, were reviewed.
  
  
  RESULTS
  With regard to overall survival, at univariate statistical analysis, the patient's age at diagnosis (threshold, 45 years), primary tumour size, local cancer extension at diagnosis (subtypes of T4), extent of thyroidectomy, performance of lymph node dissection and performance of post-surgical external radiotherapy were found to be significant prognostic variables. With regard to the appearance of recurrent disease during follow-up, at univariate statistical analysis, the patient's age at initial diagnosis (threshold, 45 years), primary tumour size, local cancer extension at diagnosis (subtypes of T4), extent of thyroidectomy, performance of lymph node dissection, presence of metastatic lymph nodes, performance of post-surgical 131I therapy and performance of post-surgical external radiotherapy were found to be significant prognostic variables. At multivariate statistical analysis, the patient's age at initial diagnosis, extent of tumour, extent of thyroidectomy and performance of lymph node dissection were the only independent prognostic variables.
  
  
  CONCLUSIONS
  In our experience, an aggressive surgical approach at first diagnosis appears to offer a better prognosis in terms of both overall survival and disease-free time interval in patients with locally advanced differentiated thyroid carcinoma, especially those over 45 years of age.
authors.affiliation: Department of Surgery, University of Padova Medical School, Padova, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Rosa Pelizzo
authors.forename: Antonio
authors.initials: A
authors.lastname: Toniato
authors.forename: Isabella Merante
authors.initials: IM
authors.lastname: Boschin
authors.forename: Andrea
authors.initials: A
authors.lastname: Piotto
authors.forename: Paolo
authors.initials: P
authors.lastname: Bernante
authors.forename: Costantino
authors.initials: C
authors.lastname: Pagetta
authors.forename: Margherita
authors.initials: M
authors.lastname: Palazzi
authors.forename: Anna
authors.initials: A
authors.lastname: Maria Guolo
authors.forename: Paolo
authors.initials: P
authors.lastname: Preo
authors.forename: Otello
authors.initials: O
authors.lastname: Nibale
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007558:Italy / Q000453:epidemiology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000706:statistics & numerical data*; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D013965:Thyroidectomy / Q000706:statistics & numerical data*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals